Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 4,589 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Crossover Clear all
Completed Phase 4 Interventional Results available

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

NCT02730351
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/ Vilanterol 100 mcg/25 mcg, Fluticasone propionate 250 mcg, Placebo via ELLIPTA inhaler, Placebo via DISKUS / ACCUHALER
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 50 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Huntington Beach, California • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

NCT06715683
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986278 Batched method, Dose A, BMS-986278 Batched method, Dose B, BMS-986278 Continuous method
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye

NCT02313454
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Intranasal Tear Neurostimulator
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Not applicable Interventional

Disruptive bEhavior manageMEnt ANd Prevention in Hospitalized Patients Using a behaviORal Intervention Team

NCT03777241
View directory record Official record
Conditions
Behavioral Problem
Interventions
Behavioral Intervention Team, Standard of care
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

NCT06290102
View directory record Official record
Conditions
Asthma
Interventions
TEV-56248, Fp MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Mobile, Alabama • Long Beach, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

NCT02344303
View directory record Official record
Conditions
Healthy
Interventions
TRV130, Moxifloxacin, Placebo
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 23, 2026, 8:18 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Enhancing the Natriuretic Peptide System in HFpEF

NCT05279742
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
Interventions
MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
Drug
Lead sponsor
Horng Chen
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 23, 2026, 8:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Optimizing Gait Symmetry After Stroke Using Mechanical Constraints and Sensory Feedback

NCT07087769
View directory record Official record
Conditions
Stroke, Split-belt Treadmill, Resistance Exercise, Feedback, Gait Training
Interventions
Treadmill Walking with Split-Belt and/or Tied-Belt Conditions, Mechanical Resistance (Pelvis and/or Ankle) depending on participant's walking capacity, Sensory Feedback Training
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
20 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

NCT00863941
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg XL Tablet, single dose, Wellbutrin XL® 150 mg Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise-induced Hypoalgesia and Proprioceptive Changes, Comparing Isometric to Isotonic Neck Exercises

NCT06465394
View directory record Official record
Conditions
Exercise
Interventions
Exercise
Procedure
Lead sponsor
University of South Dakota
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Vermillion, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 4 Interventional Results available

TRPV2 Agonists in the Fontan Circulation

NCT03965351
View directory record Official record
Conditions
Fontan
Interventions
Probenecid, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 23, 2026, 8:18 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

NCT03367741
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

NCT01353729
View directory record Official record
Conditions
Influenza, Human
Interventions
600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers

NCT02485431
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Deflazacort
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

NCT05455502
View directory record Official record
Conditions
Pain
Interventions
VX-548
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 23, 2026, 8:18 PM EDT
Recruiting Not applicable Interventional

Physiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure

NCT05675345
View directory record Official record
Conditions
Acute Hypoxemic Respiratory Failure
Interventions
HFNC only, HFNC + CNEP10, HFNC + CNEP20, HFNC + CNEP30
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Not applicable Interventional Results available

Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function

NCT02469077
View directory record Official record
Conditions
Chronic Pain
Interventions
6 week aerobic exercise intervention, Placebo, Morphine, naloxone
Behavioral · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 23, 2026, 8:18 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease

NCT01331122
View directory record Official record
Conditions
Gait Disorders, Neurologic
Interventions
droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 2 Interventional

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00391729
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
23
States / cities
Mesa, Arizona • Lafayette, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 2 Interventional Results available

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

NCT02109172
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
TD-4208, Placebo
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

NCT02741557
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
DTG, RPV, DTG/RPV FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Balsalazide Disodium 750 mg Capsules Under Fasting Conditions

NCT00618202
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Balsalazide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3866288 in Healthy Participants

NCT06641037
View directory record Official record
Conditions
Healthy
Interventions
LY3866288
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
19 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 23, 2026, 8:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Clinical Evaluation of Approved Contact Lenses

NCT02540122
View directory record Official record
Conditions
Vision Disorders
Interventions
Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, Marketed Contact Lens 4
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 23, 2026, 8:18 PM EDT